Alisol A

Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity^{[1][2][3][4][5][6][7]}. In Vitro:Alisol A (2.5-40 μM; 24 h) suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells^[3].
Alisol A (1-5 μM) concentration-dependently restores the levels of p-AMPK and p-ACC in HepG2 cells treated with free fatty acids (FFA)^[4].
Alisol A (40 μM; 24-72 h) inhibits the proliferation of human aortic endothelial cells (HAECs)^[5].
Alisol A (5-160 µM; 24 h) inhibits the proliferation of HCT-116 and HT-29 cells in a dose-dependent manner^[6].
In Vivo:Alisol A (100 mg/kg; i.p.; once daily; 4 weeks) significantly attenuates body weight and abdominal fat weight and activates the AMPK/ACC/SREBP-1c pathway in high-fat diet-induced obese mice^[4].
Alisol A (150 ppm; p.o.; in diet; 16 weeks) significantly reduces the aortic plaque area in ApoE^-/- mice with atherosclerosis, without obvious effect on blood lipid levels^[5].
Alisol A (25-100 mg/kg; i.g.; twice daily; 12 weeks) alleviates arterial plaque by activating AMPK/SIRT1 signaling pathway in apoE-deficient mice^[7].